Wall Street expects Legend Biotech to report Q3 2026 revenue of $302.5 million and EPS of $0.01, with the current $52.45 share price trading significantly below the $78.12 average analyst price target. Investors are primarily focused on the commercial ramp-up of Carvykti following its expansion into earlier lines of therapy for multiple myeloma.
Market participants are closely monitoring whether manufacturing capacity and supply chain optimizations can keep pace with surging global demand. The report is also expected to provide clarity on the company's path toward sustained quarterly profitability and its cash runway for further R&D expansion.